




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Correspondence

Depressive and anxiety symptoms in patients with SARS-CoV2 infection



ARTICLE INFO

Keywords:

Depression

Anxiety

COVID-19

SARS-CoV2

Dear Editor,

Coronavirus disease 2019 (COVID-19) currently represents a global health concern emerging from China and rapidly spreading worldwide (Chen et al., 2020). COVID-19 is due to severe acute respiratory syndrome (SARS)-Coronavirus2 (SARS-CoV2) infection (Chen et al., 2020). As widely known, SARS-CoV2 infection primarily causes pneumonia; however, other clinical manifestations have been documented in patients with SARS-CoV2 infection, with various degree of prevalence (Huang et al., 2020). In particular, the affection of cardio-vascular and neurological systems have been well recognized (Mao et al., 2020; Boukhris et al., 2020; Liguori et al., 2020).

In this context, we have recently performed a prospective study in 103 patients with COVID-19 admitted at the University Hospital of Tor Vergata in Rome (Liguori et al., 2020). In this patient group, we documented the frequent occurrence of subjective neurological symptoms (Liguori et al., 2020). Based on the study protocol, all patients underwent an anamnestic interview requiring a dichotomized answer (YES/NO) about 13 neurological symptoms (hyposmia, dysgeusia, auditory dysfunction, headache, confusion, dizziness, numbness/paresthesia, fatigue, daytime sleepiness, sleep impairment, muscle ache, depression, and anxiety). At the time of the interview the following parameters were also evaluated: age, sex, laboratory test (serum levels of white blood cells – WBC - and C-reactive protein – CRP), duration of hospitalization. The study design was approved by the local ethics committee at University Hospital of Tor Vergata in Rome, which approved the procedures, conformed to the Declaration of Helsinki, and informed consents were achieved from all the participants (protocol no. 48.20, version 2020).

In this secondary analysis derived from the previous investigation, (Liguori et al., 2020) we aimed at primarily focusing on the occurrence of depressive and anxiety symptoms in patients with COVID-19, also considering the possible correlation of these symptoms with the other neurological symptoms investigated and the demographic, clinical, and laboratory data achieved.

The main finding of this secondary analysis is the occurrence of anxiety symptoms in 34/103 patients and depressive symptoms in 39/103 patients with COVID-19. In particular, 27 patients complained of both depressive and anxiety symptoms, whereas seven patients experienced only anxiety symptoms and 12 only depressive symptoms (Table 1). We also found that patients with anxiety symptoms presented more frequent muscle ache, higher CRP serum levels and more

concomitant neurological symptoms than those without anxiety symptoms. Likewise, patients featured by depressive symptoms showed higher CRP, more concomitant neurological symptoms, and higher rate of anxiety and muscle ache symptoms than those not complaining for depressive symptoms (Table 1). Finally, we did not document sex-based differences related to both anxiety and depressive symptoms.

Neurological manifestations of SARS-CoV2 infection may range from subjective complaints (including headache, muscle ache, hyposmia and dysgeusia) to severe and life threatening conditions, such as encephalitis, stroke, Guillan-Barrè syndrome, and status epilepticus (Boukhris et al., 2020; Liguori et al., 2020). Moreover, psychological distress has been documented in patients with COVID-19 needing hospitalization or quarantine (Guo et al., 2020). Depression, anxiety, and post-traumatic stress symptoms were more frequent in patients with COVID-19 compared to volunteers not affected by SARS-CoV2 infection (Guo et al., 2020). Nationwide on-line or telephonic surveys (mostly performed in China) reported a sex effect on psychological outcomes, with women showing significantly higher psychological distress than men (Bo et al., 2020; Liu et al., 2020; Qiu et al., 2020).

In this study, we did not document differences in anxiety and depressive complaints between men and women. However, we exclusively perform an anamnestic interview with a dichotomized answer to detect anxiety and depression, and not a validated questionnaire or a psychological interview.

We also analyzed white blood cells and CRP in patients with SARS-CoV2 infection. The comparison between patients with and without depressive or anxiety symptoms did not document significant differences in WBC, but showed higher CRP in patients with anxiety or depressive symptoms. Our results partially concord with the data reported by Guo and co-Authors, since in this latter study a correlation between inflammatory markers and psychological distress was evident only in patients with severe depressive symptoms (Guo et al., 2020). Finally, we documented the presence of more concomitant neurological symptoms in patients with anxiety or depressive symptoms. This result can be explained by a higher psychological burden in patients with several neurological symptoms, or by a more severe nervous system involvement also producing depression and anxiety. The neurobiological basis of these symptoms, indeed, have been widely recognized, and SARS-CoV2 seems to affect the nervous system via different mechanisms (Wu et al., 2020). The disproportionate inflammatory response, the direct brain invasion by the virus, or the activation of T cells affecting nervous system have been considered as events leading to nervous system damage in

<https://doi.org/10.1016/j.jad.2020.09.042>

Received 18 June 2020; Accepted 9 September 2020

Available online 14 September 2020

0165-0327/ © 2020 Elsevier B.V. All rights reserved.

Table 1
Demographic, Clinical, Laboratory, and Neurological Data of patients with SARS-CoV2 infection.

	Anxiety		P Value	Depression		P Value
	Yes (N = 34)	No (N = 69)		Yes (N = 39)	No (N = 64)	
Sex (M, F)	18, 16	41, 28	NS	19, 20	40, 24	NS
Age (Mean ± SD)	56,71 ± 12,76	54 ± 14,88	NS	57,82 ± 14,45	53,3 ± 13,92	NS
CRP (Mean ± SD)	32,15 ± 45,97	14,05 ± 26,14	0,039	34,37 ± 49,41	11,43 ± 16,55	0,023
WBC (x10 ⁹ /L) (Mean ± SD)	9,71 ± 7,82	7,97 ± 5,31	NS	8,53 ± 4,57	8,55 ± 7,18	NS
Neutrophil, count (Mean ± SD)	5,85 ± 4,51	5,91 ± 5,6	NS	6,4 ± 4,52	5,55 ± 5,69	NS
Lymphocyte, count (Mean ± SD)	3,15 ± 7,57	1,57 ± 0,69	NS	1,41 ± 0,86	2,54 ± 5,56	NS
Neutrophil,%WBC (Mean ± SD)	0,65 ± 0,22	0,66 ± 0,16	NS	0,7 ± 0,15	0,62 ± 0,2	NS
Lymphocyte,%WBC (Mean ± SD)	0,24 ± 0,21	0,24 ± 0,12	NS	0,19 ± 0,12	0,27 ± 0,17	NS
Days of Hospitalization (Mean ± SD)	7,69 ± 7,13	8,53 ± 8,6	NS	8,41 ± 7,09	8,16 ± 8,65	NS
Temperature (Mean ± SD)	36,61 ± 0,84	36,51 ± 0,61	NS	36,55 ± 0,79	36,53 ± 0,64	NS
Hyposmia n	14	24	NS	14	24	NS
Dysgeusia n	16	29	NS	18	27	NS
Auditory Dysfunction n	0	2	NS	2	0	NS
Headache n	17	25	NS	17	25	NS
Confusion n	11	12	NS	11	12	NS
Dizziness n	11	16	NS	12	15	NS
Numbness/Paresthesia n	0	4	NS	1	3	NS
Fatigue n	12	18	NS	11	19	NS
Daytime Sleepiness n	14	18	NS	11	21	NS
Sleep Impairment n	17	30	NS	19	28	NS
Muscle Ache n	16	17	0,008	13	20	0,042
Depression n	25	11	0,0001	NA	NA	NA
Anxiety n	NA	NA	NA	25	10	0,0001
N Symptoms (Mean ± D)	5,3 ± 2,17	3,03 ± 2,48	0,0001	5,2 ± 2,11	3,04 ± 2,54	0,0001

List of Abbreviations: F, female; M, male; n, number; SD, standard deviation; NS, not significant; NA, not admitted; WBC, white blood cells; CRP, C-reactive protein.

patients with COVID-19 (Wu et al., 2020). Hence, the neurotropic activity of the SARS-CoV2 may also explain the occurrence of neuropsychiatric symptoms by activation of immune-inflammatory responses (Wu et al., 2020).

Hence, depression and anxiety are frequent symptoms in patients with SARS-CoV2 infection needing careful medical evaluation and follow-up. Moreover, counteracting these neuropsychological symptoms can improve the reaction to the infection and can need of specific treatments in order to improve the possibility of rehabilitation and recovery.

DISCLOSURE STATEMENT: This was not an industry-supported study. The authors have indicated no financial conflicts of interest. No acknowledgements are present. No fundings are present for this study.

Author contributions

NC, MI, JO, GP, EP, OB, GGM contributed with patients' selection and evaluation

CL, MP, MS contributed to data acquisition and analysis

CL, MP contributed to drafting the manuscript and figures

CL, MP, NBM, MA, LS, PR, AM conceived and designed the study, supervised data analysis, contributed to drafting and revising the manuscript

Declaration of Competing Interest

All authors present no conflicts of interest.

References

- Bo, H.X., Li, W., Yang, Y., et al., 2020. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. *Psychol. Med.* 1–7. <https://doi.org/10.1017/S0033291720000999>.
- Boukhris, M., Hillani, A., Moroni, F., et al., 2020 May 16. Cardiovascular implications of the COVID-19 pandemic: a global perspective. *Can J Cardiol.* <https://doi.org/10.1016/j.cjca.2020.05.018>.
- Chen, N., Zhou, M., Dong, X., et al., 2020 Feb 15. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan. China: a

descriptive study. *Lancet* 395 (10223), 507–513.

- Guo, Q., Zheng, Y., Shi, J., et al., 2020 May 19. Immediate Psychological Distress in Quarantined Patients With COVID-19 and Its Association With Peripheral Inflammation: a Mixed-Method Study. *Brain Behav Immun.* <https://doi.org/10.1016/j.bbi.2020.05.038>.
- Huang, C., Wang, Y., Li, X., et al., 2020 Feb 15. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. *Lancet* 395 (10223), 497–506.
- Liguori, C., Pierantozzi, M., Spanetta, M., et al., 2019. Subjective Neurological Symptoms Frequently Occur in Patients With SARS-CoV2 Infection. *Brain Behav Immun.* <https://doi.org/10.1016/j.bbi.2020.05.037>.
- Liu, N., Zhang, F., Wei, C., et al., 2020. Prevalence and predictors of PTSS during COVID-19 Outbreak in China Hardest-hit Areas: gender differences matter. *Psychiatry Res* 287. <https://doi.org/10.1016/j.psychres.2020.112921>.
- Mao, L., Jin, H., Wang, M., et al., 2020 Apr 10. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan. China. *JAMA Neurol.* <https://doi.org/10.1001/jamaneurol.2020.1127>.
- Qiu, J., Shen, B., Zhao, M., Wang, Z., Xie, B., Xu, Y., 2020. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. *Gen. Psychiatr.* 33. <https://doi.org/10.1136/gpsych-2020-100213>.
- Wu, Y., Xu, X., Chen, Z., et al., 2020 Mar 30. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun.* <https://doi.org/10.1016/j.bbi.2020.03.03>.

Claudio Liguori^{a,b,*}, Mariangela Pierantozzi^{a,b}, Matteo Spanetta^b, Loredana Sarmati^{b,c}, Novella Cesta^c, Marco Iannetta^{b,c}, Josuel Ora^d, Grazia Genga Mina^e, Ermanno Puxeddu^{d,f}, Ottavia Balbi^e, Gabriella Pezzuto^d, Andrea Magrini^c, Paola Rogliani^{d,f}, Massimo Andreoni^{b,c}, Nicola Biagio Mercuri^{a,b,g}

^a Neurology Unit, University Hospital "Tor Vergata", Rome, Italy

^b Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

^c Infectious Diseases Clinic, University Hospital "Tor Vergata", Rome, Italy

^d Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, Italy

^e Occupational Medicine Department, University of Rome "Tor Vergata", Rome, Italy

^f Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy

^g IRCCS Santa Lucia Foundation, Rome, Italy

E-mail address: dott.claudioliguori@yahoo.it (C. Liguori).

* Correspondence author: Claudio Liguori, Neurology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Viale Oxford 81 00133 Rome, Italy.